Clinical Trial Update: Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abatacept-based immunosuppression to prevent acute graft-versus-host disease during unrelated donor hematopoietic cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Boston Children's Hospital | Conditions: AML, ALL | Phase 2 | Status: COMPLETED | Results posted: 2017-09-15